Corcept Therapeutics Incorporated (CORT) — Cash Flow Quality Index
Corcept Therapeutics Incorporated (CORT) has a Cash Flow Quality Index of 0.39x as of December 2025. Operating cash flow of $38.45 Million is below net income of $98.17 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore CORT operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Corcept Therapeutics Incorporated Cash Flow Quality Index (2016–2025)
Historical Cash Flow Quality Index for Corcept Therapeutics Incorporated across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see CORT cash flow conversion.
Annual Cash Flow Quality Index for Corcept Therapeutics Incorporated (2016–2025)
Year-by-year earnings quality comparison for Corcept Therapeutics Incorporated.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.45x | $142.00 Million | $98.17 Million | ▲ +3.1% |
| 2024 | 1.40x | $198.07 Million | $141.21 Million | ▲ +17.2% |
| 2023 | 1.20x | $127.04 Million | $106.14 Million | ▲ +0.9% |
| 2022 | 1.19x | $120.32 Million | $101.42 Million | ▼ -20.5% |
| 2021 | 1.49x | $167.89 Million | $112.51 Million | ▲ +4.1% |
| 2020 | 1.43x | $151.97 Million | $106.01 Million | ▼ -0.8% |
| 2019 | 1.45x | $136.12 Million | $94.18 Million | ▼ -5.8% |
| 2018 | 1.53x | $115.67 Million | $75.41 Million | ▲ +225.0% |
| 2017 | 0.47x | $60.94 Million | $129.12 Million | ▼ -79.1% |
| 2016 | 2.26x | $18.39 Million | $8.14 Million | — |